Agitation in Alzheimer Disease: What Clinicians Need to Ask, Assess, and Address
A geriatric psychiatrist's clinical pearls on agitation in AD, incluiding behavioral cues, triggers, and evidence-based treatment strategies for primary care.
Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes
Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.
Multicancer Early Detection Tests Cut Stage IV Diagnoses by Nearly Half Over 10 Years
A 10-year microsimlation model of annual MCED testing revealed signficant reductions in late-stage cancer diagnoses, particularly for cancers lacking routine screening,
Real-World Study Shows Intranasal Epinephrine Effectively Treats Most Allergic Reactions with a Single Dose
Intranasal epinephrine emerges as a promising, needle-free solution for treating severe allergic reactions, showing high effectiveness and usability in clinical settings.
Understanding Alzheimer’s Agitation: Survey Points to Missed Diagnoses and Caregiver Burden
Many caregivers, both paid and unpaid, miss or misinterpret agitation symptoms in Alzheimer disease, fueling stress, stigma, and delayed medical support.
Donna Plecha, MD: The Real Barriers to Optimal Breast Cancer Screening in Women with Dense Breasts
Access, cost, and clinician awareness remain significant barriers to implementing supplemental breast screening, according to Plecha.
Donna Plecha, MD: What PCPs Need to Know About the Dense Breast Notification Law
Breast imaging expert Donna M. Plecha, MD, explains the FDA's dense breast notification requirement and when to recommend supplemental MRI screening.
Initiating Menopausal Hormone Therapy in Primary Care: Where to Start, With Harvard's Caroline Mitchell, MD, MPH
Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.
Semaglutide 2.4 mg Improves Liver Health in Patients with MASH, Even at Low Levels of Weight Loss
AASLD 2025: Semaglutide 2.4 mg shows promise in improving liver health in adults with MASH, regardless of weight loss, according to new trial findings.
Metformin May Be Effective Treatment for Atrial Fibrillation in Adults wtih Obesity and Without Diabetes
Research reveals metformin's potential to enhance sinus rhythm stability post-ablation for AF in adults with obesity, independent of weight loss.
Digital Screening Tool Duo Shows Promise for ADRD Detection in Primary Care
Indiana University study found that integrating patient-reported outcome questionnaires with machine learning boosts dementia diagnoses by 31% in primary care settings.
Large-Scale Study Challenges Previous Research on Menopause and Brain Structure
TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.
Mayo Clinic Researcher on Why Menopause Stage Matters in Metabolic Research
TMS 2025: Regina Castaneda, MD, explains why reproductive stage is a critical variable in obesity and metabolic research.
Tapinarof Cream 1%, Shows Early and Durable Response in Children With Atopic Dermatitis
ACAAI 2025. Phase 3 data show tapinarof cream provides early, sustained improvement and good tolerability in children aged ≥2 years with atopic dermatitis.
Vitamin D Dosing Tailored to Optimal Levels Reduced Risk of Recurrent MI by More Than Half
The TARGET-D trial found targeted vitamin D dosing post-MI didn’t lower MACE but reduced recurrent MI risk, supporting individualized serum-level management.
Cushing Syndrome: Clinical Features, Screening Tests, and When to Refer
Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.
Sublingual Epinephrine Film Well Tolerated in Children, Matches Efficacy Seen in Adults
Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.
FDA to Remove “Black Box” Warnings from Hormone Replacement Therapy Products
Regulatory update aims to align labeling with current evidence on menopausal hormone therapy safety and benefits
Investigational Oral PCSK-9 Inhibitor Reduces LDL-C by 60% in Late Stage HeFH Trial
Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.
Primary Care Training Drives Higher Adoption and Continued Use of LARC Methods: Daily Dose
Your daily dose of the clinical news you may have missed.
Treg-Targeting Rezpegaldesleukin Demonstrates Dual Benefit for Asthma and Atopic Dermatitis
Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.
UPDATED: Phase 3 VESALIUS-CV Trial Demonstrates Evolocumab Reduces Cardiovascular Events in High-Risk Adults Without Prior Heart Attack or Stroke
The findings showed evolocumab reduced risk of first major MACE by 25% and risk of first MI by 36%. Full study findings are published in NEJM.
Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease
Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.
FMX 2025: 6 Takeaways for Primary Care Physicians
Explore key clinical takeaways from FMX 2025, including updates on CGM, chronic cough, AAA screening, immunization, and more.
Weekly Dose Podcast: Global Diabetes Gaps, Declining Salt Substitute Use, Flu Vaccine Safety, Vaginal Estradiol, and Preconception CT Risks
This new episode covers global diabetes gaps, salt substitute use, influenza vaccine safety, vaginal estradiol, and preconception CT risks.
Dupilumab Meets All Endpoints in Phase 3 Study for Allergic Fungal Rhinosinusitis; FDA Grants Priority Review
ACAAI 2025: Phase 3 results show dupilumab significantly reduced sinus opacification, nasal congestion, and polyp size in patients with AFRS.
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose
CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial
Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.
Diabetes Self-Management at Work: A Checklist for Clinicians
Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.
Hormone Therapy and Autoimmune Disease: Early Findings Raise New Questions for Postmenopausal Care
New research suggests hormone therapy may increase autoimmune disease risk in postmenopausal women. Dr Jiang discusses early findings and clinical implications.
